Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections

View/ Open
Issue date
2018Author
Novell, Elena
Tarancón, Vicens
Borrás, Francesc E.
Montoya, Maria
del Portillo, Hernando A.
Suggested citation
Montaner Tarbes, Sergio Roberto;
Novell, Elena;
Tarancón, Vicens;
Borrás, Francesc E.;
Montoya, Maria;
Fraile Sauce, Lorenzo José;
del Portillo, Hernando A.;
.
(2018)
.
Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections.
Scientific Reports, 2018, vol.8, núm.17487, p 1-10.
https://doi.org/10.1038/s41598-018-36141-5.
Metadata
Show full item recordAbstract
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the
most important swine diseases with a significant economic burden worldwide. Unfortunately, available
vaccines are partially effective highlighting the need of novel approaches. Previously, antigenic viral
proteins were described in serum-derived extracellular vesicles (EVs) from pigs previously infected with
PRRSV. Here, a targeted-pig trial was designed to determine the safety and immunogenicity of such
extracellular vesicles enriched fractions. Our results showed that immunizations with EV-enriched
fractions from convalescence animals in combination with montanide is safe and free of virus as
immunizations with up-to two milligrams of EV-enriched fractions did not induce clinical symptoms,
adverse effects and detectable viral replication. In addition, this vaccine formulation was able to elicit
specific humoral IgG immune response in vaccinated animals, albeit variably. Noticeably, sera from
vaccinated animals was diagnosed negative when tested for PRRSV using a commercial ELISA test;
thus, indicating that this new approach differentiates vaccinated from infected animals. Lastly, after
priming animals with EV-enriched fractions from sera of convalescence animals and boosting them with
synthetic viral peptides identified by mass spectrometry, a distinctive high and specific IFN-γ response
was elicited. Altogether, our data strongly suggest the use of serum EV-enriched fractions as a novel
vaccine strategy against PRRSV.
Is part of
Scientific Reports, 2018, vol.8, núm.17487, p 1-10European research projects
Collections
The following license files are associated with this item: